FinlandFinland

Major Parkinson's Study Launched

13.11.2004

Espoo - “Dyskinesias often become a serious problem for people with Parkinson's disease. Delaying the onset of these motor complications would therefore offer a real improvement in the quality of life for patients and their families,” said Mary Baker, President of the European Parkinson's Disease Association (EPDA), UK. She welcomed the major study STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation) in Parkinson's disease (PD), which was recently launched by Orion Pharma, a joint business division of Orion Corporation and Novartis.
This study seeks to investigate whether - when used as initial therapy - the optimized Levodopa medication Stalevo, which contains Levodopa, Carbidopa and Entacapone, delays the onset of motor complications, such as dyskinesias, compared with the traditional formulation of Levodopa/Carbidopa. STRIDE-PD will enroll some 740 patients at 70 centres in 14 countries: Austria, Belgium, Canada, France, Finland, Germany, Greece, Italy, Spain, Sweden, Turkey, Switzerland, the United Kingdom and the USA. The first study results are expected in 2007. “If the study shows that Stalevo is superior to the traditional therapy up to the time of onset of dyskinesias, this could change the current treatment paradigm completely,” said Werner Poewe, Chair of the Depart-ment of Neurology at Innsbruck University, Austria. “We would then use Stalevo from the first day in patients needing Levodopa treatment.”
Levodopa is the most effective and most widely used symptomatic PD treatment for nearly 40 years. However, after several years of treatment with Levodopa, patients often begin to experience motor complications, such as “wearing-off” (when the effect of one dose of medication does not last until the next scheduled dose) and dyskinesias.

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/article/major-parkinsons-study-launched.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014


Current issue

All issues

Product of the week

Products